{"id":22792,"date":"2025-03-27T15:27:09","date_gmt":"2025-03-27T15:27:09","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/riprendere-slancio-nellinnovazione-biofarmaceutica\/"},"modified":"2025-03-28T10:43:06","modified_gmt":"2025-03-28T10:43:06","slug":"riprendere-slancio-nellinnovazione-biofarmaceutica","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/","title":{"rendered":"Regains momentum in Biopharma Innovation"},"content":{"rendered":"<p id=\"tw-target-text\" class=\"tw-data-text tw-text-large tw-ta\" dir=\"ltr\" data-placeholder=\"Translation\" data-ved=\"2ahUKEwj7kveNyqyMAxWZgf0HHdHRL3UQ3ewLegQIFRAV\" aria-label=\"Translated text: After the turbulent years of the pandemic, the biopharmaceutical research and development sector is regaining ground. This is what emerges from the Global Trends in R&amp;D 2025, published by IQVIA Institute: in 2024, global funding reached 102 billion dollars, while clinical trials returned to pre-COVID levels. Emerging companies are driving innovation, with a growing role of China and technologies such as RNA, radiotherapies and artificial intelligence. But critical issues remain to be addressed: long times, high costs and geographical heterogeneity.\"><span class=\"Y2IQFc\" lang=\"en\">After the turbulent years of the pandemic, the biopharmaceutical research and development sector is regaining ground. This is what emerges from the <strong><em>Global Trends in R&amp;D 2025<\/em><\/strong>, published by IQVIA Institute: in 2024, <strong>global funding reached 102 billion dollars<\/strong>, while clinical trials returned to pre-COVID levels. Emerging companies are driving innovation, with a growing role of China and technologies such as RNA, radiotherapies and artificial intelligence. But critical issues remain to be addressed: long times, high costs and geographical heterogeneity.<\/span><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/iqvia-institute-rd-trends-2025-forweb.pdf\" target=\"_blank\" rel=\"noopener\"><span class=\"td_btn td_btn_md td_default_btn\">Read the Report<\/span><\/a><\/p>\n<h2 data-start=\"825\" data-end=\"882\">R&amp;D Funding: A New Spring After the Pandemic Slowdown<\/h2>\n<p class=\"\" data-start=\"884\" data-end=\"1245\">In 2024, <strong>global biopharma R&amp;D funding reached $102 billion<\/strong>, marking the third-highest level of the decade and confirming a second consecutive year of post-pandemic growth. This surge was primarily driven by follow-on funding, which accounted for 45% of the total, reaching $46 billion \u2014 up 77% from the previous year\u200b.<\/p>\n<p class=\"\" data-start=\"1247\" data-end=\"1594\">Although IPO activity recovered slightly ($7 billion in 2024), it remained historically low. M&amp;A activity, while slightly down in number (from 86 to 81 deals), saw its median deal value soar from $153 million to $405 million. Deals in the $1\u20135 billion range doubled, accounting for $51 billion in value\u200b.<\/p>\n<h2 data-start=\"1596\" data-end=\"1643\">Emerging Biotech: The New Innovation Engine<\/h2>\n<p class=\"\" data-start=\"1645\" data-end=\"2106\">A defining shift is the <strong>growing prominence of Emerging Biopharma (EBP) companies<\/strong> \u2014 defined as firms spending under $200 million annually on R&amp;D. These companies accounted for 66% of all new deals in 2024 and continue to demonstrate increasing independence. In 2015, EBPs sponsored 42% of Phase II studies; by 2024, that figure rose to 64%. Even in the complex Phase III trials, they now hold the majority share (56%)\u200b.<\/p>\n<h2 data-start=\"2108\" data-end=\"2180\">Therapies of the Future: RNA, radiopharma and bispecific antibodies<\/h2>\n<p class=\"\" data-start=\"2182\" data-end=\"2474\">Innovation is accelerating in diverse areas. Over the past five years, deals involving RNA-based therapies and radiopharmaceuticals have more than doubled. A standout example in 2024 was Sarepta&#8217;s $13 billion investment in Arrowhead&#8217;s RNA platform\u200b.<\/p>\n<p class=\"\" data-start=\"2476\" data-end=\"2748\">In oncology, new modalities such as bispecific antibodies, antibody-drug conjugates (ADCs), CAR-T therapies, and gene therapies now account for 35% of trials \u2014 a sign of the shift toward more precise and personalized treatments\u200b.<\/p>\n<h2 data-start=\"2750\" data-end=\"2803\">AI and Drug Development: from Promise to Practice<\/h2>\n<p class=\"\" data-start=\"2805\" data-end=\"3201\">Artificial intelligence has emerged as a structural driver of innovation. In 2024, twelve AI\/ML-related life sciences deals surpassed $200 million each, totaling $9.7 billion. Notably, Isomorphic Labs secured nearly $3 billion in deals with Eli Lilly and Novartis, while Generate:Biomedicines partnered with Novartis for AI-driven protein optimization\u200b.<\/p>\n<p class=\"\" data-start=\"3203\" data-end=\"3395\">AI is becoming operational: FDA submissions involving AI jumped from 14 in 2020 to 170 in 2022. In January 2025, the FDA released draft guidance on AI\/ML use in drug and biologics development.<\/p>\n<h2 data-start=\"3397\" data-end=\"3466\">Clinical Trials: stable volume, shifting geography and priorities<\/h2>\n<p class=\"\" data-start=\"3468\" data-end=\"3757\">Clinical trial starts in 2024 totaled 5,318 \u2014 matching pre-pandemic levels from 2019. However, geographic and therapeutic shifts are notable. The U.S. maintained its lead (35% of trial starts), while China reached 30% and Europe declined to 21%\u200b.<\/p>\n<p class=\"\" data-start=\"3759\" data-end=\"4045\"><strong>Oncology remains dominant<\/strong> (41% of all trials), but obesity is the fastest-growing area: trial starts rose 77% year-over-year in 2024. There are now 173 anti-obesity drugs in development, many based on GLP-1 agonists and combination therapies\u200b.<\/p>\n<p class=\"\" data-start=\"4047\" data-end=\"4218\">Conversely, infectious disease trials \u2014 excluding COVID-19 \u2014 fell by 176 studies compared to 2019, raising concerns about the pipeline for antibiotic-resistant infections.<\/p>\n<h2 data-start=\"4220\" data-end=\"4270\">Productivity and complexity: still a challenge<\/h2>\n<p class=\"\" data-start=\"4272\" data-end=\"4550\"><strong>IQVIA\u2019s Clinical Program Productivity Index<\/strong> (CPPI) shows a slight productivity improvement in 2024, thanks to better Phase III success rates. However, trial enrollment times are increasing, especially in oncology (median: 25+ months)\u200b.<\/p>\n<p class=\"\" data-start=\"4552\" data-end=\"4779\">Trials are also growing more complex: more sites and subjects per study, even as inclusion\/exclusion criteria remain tight. Adaptive designs, decentralized trials, and real-world data are key enablers for future R&amp;D efficiency.<\/p>\n<h2 data-start=\"4781\" data-end=\"4807\">China\u2019s strategic rise<\/h2>\n<p class=\"\" data-start=\"4809\" data-end=\"5073\">The report highlights China&#8217;s growing role: between 2020 and 2024, China launched 76 NAS exclusively for its domestic market \u2014 up from just 9 in the previous five years. Median launch lag decreased from 7.5 to 3.7 years\u200b.<\/p>\n<p class=\"\" data-start=\"5075\" data-end=\"5261\">Importantly, 71 of the 73 China-related international deals in 2024 involved out-licensing or acquisition by U.S. or European companies, reinforcing China&#8217;s \u201cfor-the-world\u201d R&amp;D strategy.<\/p>\n<h2 data-start=\"5268\" data-end=\"5282\">And in the 2025?<\/h2>\n<p class=\"\" data-start=\"5284\" data-end=\"5461\">This year begins with strong momentum in biopharma R&amp;D: funding is rising, emerging biotech firms are leading innovation, and technologies like AI and RNA are reshaping the pipeline.<\/p>\n<p class=\"\" data-start=\"5463\" data-end=\"5730\">Still, significant hurdles remain: longer development timelines, declining attention to infectious diseases, and increased trial complexity. The future of innovation will rely on more agile development models, smarter collaborations, and broader global participation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Global Trends in R&#038;D 2025, IQVIA report reveals renewed dynamism in the R&#038;D sector amid record funding, growth of emerging biotechs and new therapeutic modalities<\/p>\n","protected":false},"author":32,"featured_media":22790,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[793],"tags":[],"class_list":{"0":"post-22792","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-insights-en"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Regains momentum in Biopharma Innovation - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"Global Trends in R&amp;D 2025 reveals renewed R&amp;D dynamism: Record Funding, Biotech Growth, and New Therapeutic Modalities\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regains momentum in Biopharma Innovation - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Global Trends in R&amp;D 2025 reveals renewed R&amp;D dynamism: Record Funding, Biotech Growth, and New Therapeutic Modalities\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-27T15:27:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-28T10:43:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1435\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\"},\"headline\":\"Regains momentum in Biopharma Innovation\",\"datePublished\":\"2025-03-27T15:27:09+00:00\",\"dateModified\":\"2025-03-28T10:43:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/\"},\"wordCount\":705,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg\",\"articleSection\":[\"Insights\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/\",\"name\":\"Regains momentum in Biopharma Innovation - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg\",\"datePublished\":\"2025-03-27T15:27:09+00:00\",\"dateModified\":\"2025-03-28T10:43:06+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\"},\"description\":\"Global Trends in R&D 2025 reveals renewed R&D dynamism: Record Funding, Biotech Growth, and New Therapeutic Modalities\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg\",\"width\":2560,\"height\":1435,\"caption\":\"Abstract Hexagons Connected With Lines Blue Green Orange White Background Graphic Design Illustration.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regains momentum in Biopharma Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regains momentum in Biopharma Innovation - MakingPharmaIndustry","description":"Global Trends in R&D 2025 reveals renewed R&D dynamism: Record Funding, Biotech Growth, and New Therapeutic Modalities","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/","og_locale":"en_US","og_type":"article","og_title":"Regains momentum in Biopharma Innovation - MakingPharmaIndustry","og_description":"Global Trends in R&D 2025 reveals renewed R&D dynamism: Record Funding, Biotech Growth, and New Therapeutic Modalities","og_url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2025-03-27T15:27:09+00:00","article_modified_time":"2025-03-28T10:43:06+00:00","og_image":[{"width":2560,"height":1435,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg","type":"image\/jpeg"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09"},"headline":"Regains momentum in Biopharma Innovation","datePublished":"2025-03-27T15:27:09+00:00","dateModified":"2025-03-28T10:43:06+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/"},"wordCount":705,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg","articleSection":["Insights"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/","url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/","name":"Regains momentum in Biopharma Innovation - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg","datePublished":"2025-03-27T15:27:09+00:00","dateModified":"2025-03-28T10:43:06+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09"},"description":"Global Trends in R&D 2025 reveals renewed R&D dynamism: Record Funding, Biotech Growth, and New Therapeutic Modalities","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/03\/AdobeStock_1254875252-scaled.jpeg","width":2560,"height":1435,"caption":"Abstract Hexagons Connected With Lines Blue Green Orange White Background Graphic Design Illustration."},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/insights-en\/riprendere-slancio-nellinnovazione-biofarmaceutica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Regains momentum in Biopharma Innovation"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/5e59d6ee887eb3eafd7887d214ff1a09","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/22792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=22792"}],"version-history":[{"count":6,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/22792\/revisions"}],"predecessor-version":[{"id":22799,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/22792\/revisions\/22799"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/22790"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=22792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=22792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=22792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}